Novo Nordisk (NVO) reportedly plans to phase out production of its human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic.

The Danish drugmaker plans to make human insulin only available in vials, which would

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.